The Clinical Impact of Bet v 6 in Birch Pollen-Sensitized Patients

Publisher： Karger

E-ISSN： 1423-0097|173|1|34-43

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.173, Iss.1, 2017-05, pp. : 34-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Relevance of IgE to Profilin and/or Polcalcin in Pollen-Sensitized Patients

By  

International Archives of Allergy and Immunology, Vol. 169, Iss. 2, 2016-04 ,pp. : 101-107

Karger

Access to resources Recommend Favorite

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 1, 2005-09 ,pp. : 59-66

Karger

Access to resources Recommend Favorite

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients

By  

ALLERGY, Vol. 70, Iss. 7, 2015-07 ,pp. : 795-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of Bet v1, Bet v2 and Bet v4 Specific IgE Antibodies in the Sera of Children and Adult Patients Allergic to Birch Pollen: Evaluation of Different IgE Reactivity Profiles Depending on Age and Local Sensitization

By  

International Archives of Allergy and Immunology, Vol. 154, Iss. 4, 2010-10 ,pp. : 278-285

Karger

Access to resources Recommend Favorite

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite